{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "34012108",
  "DateCompleted": {
    "Year": "2021",
    "Month": "06",
    "Day": "17"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "12",
    "Day": "07"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2021",
        "Month": "05",
        "Day": "19"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10617",
      "10.1038/s41598-021-89957-z"
    ],
    "Journal": {
      "ISSN": "2045-2322",
      "JournalIssue": {
        "Volume": "11",
        "Issue": "1",
        "PubDate": {
          "Year": "2021",
          "Month": "May",
          "Day": "19"
        }
      },
      "Title": "Scientific reports",
      "ISOAbbreviation": "Sci Rep"
    },
    "ArticleTitle": "A super-potent tetramerized ACE2 protein displays enhanced neutralization of SARS-CoV-2 virus infection.",
    "Pagination": {
      "StartPage": "10617",
      "MedlinePgn": "10617"
    },
    "Abstract": {
      "AbstractText": [
        "Approaches are needed for therapy of the severe acute respiratory syndrome from SARS-CoV-2 coronavirus (COVID-19). Interfering with the interaction of viral antigens with the angiotensin converting enzyme 2 (ACE-2) receptor is a promising strategy by blocking the infection of the coronaviruses into human cells. We have implemented a novel protein engineering technology to produce a super-potent tetravalent form of ACE2, coupled to the human immunoglobulin \u03b31 Fc region, using a self-assembling, tetramerization domain from p53 protein. This high molecular weight Quad protein (ACE2-Fc-TD) retains binding to the SARS-CoV-2 receptor binding spike protein and can form a complex with the spike protein plus anti-viral antibodies. The ACE2-Fc-TD acts as a powerful decoy protein that out-performs soluble monomeric and dimeric ACE2 proteins and blocks both SARS-CoV-2 pseudovirus and SARS-CoV-2 virus infection with greatly enhanced efficacy. The ACE2 tetrameric protein complex promise to be important for development as decoy therapeutic proteins against COVID-19. In contrast to monoclonal antibodies, ACE2 decoy is unlikely to be affected by mutations in SARS-CoV-2 that are beginning to appear in variant forms. In addition, ACE2 multimeric proteins will be available as therapeutic proteins should new coronaviruses appear in the future because these are likely to interact with ACE2 receptor."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Institute of Cancer Research, 15 Cotswold Road, Sutton, London, SM2 5NG, UK."
          }
        ],
        "LastName": "Miller",
        "ForeName": "Ami",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Institute of Cancer Research, 15 Cotswold Road, Sutton, London, SM2 5NG, UK."
          }
        ],
        "LastName": "Leach",
        "ForeName": "Adam",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Institute of Cancer Research, 15 Cotswold Road, Sutton, London, SM2 5NG, UK."
          }
        ],
        "LastName": "Thomas",
        "ForeName": "Jemima",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Institute of Cancer Research, 15 Cotswold Road, Sutton, London, SM2 5NG, UK."
          }
        ],
        "LastName": "McAndrew",
        "ForeName": "Craig",
        "Initials": "C"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Hertfordshire, EN6 3QG, UK."
          }
        ],
        "LastName": "Bentley",
        "ForeName": "Emma",
        "Initials": "E"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Hertfordshire, EN6 3QG, UK."
          }
        ],
        "LastName": "Mattiuzzo",
        "ForeName": "Giada",
        "Initials": "G"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of LABMED, National Veterinary Institute (SVA), 751 89, Uppsala, Sweden."
          },
          {
            "Identifier": [],
            "Affiliation": "Karolinska Institute, 17177, Stockholm, Sweden."
          }
        ],
        "LastName": "John",
        "ForeName": "Lijo",
        "Initials": "L"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of LABMED, National Veterinary Institute (SVA), 751 89, Uppsala, Sweden."
          },
          {
            "Identifier": [],
            "Affiliation": "Karolinska Institute, 17177, Stockholm, Sweden."
          }
        ],
        "LastName": "Mirazimi",
        "ForeName": "Ali",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Research Complex at Harwell, Rutherford Appleton Laboratory, Oxon, OX11 0FA, UK."
          }
        ],
        "LastName": "Harris",
        "ForeName": "Gemma",
        "Initials": "G"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Membrane Protein Laboratory, Diamond Light Source, Harwell Science and Innovation Campus, Didcot, OX11 0DE, UK."
          }
        ],
        "LastName": "Gamage",
        "ForeName": "Nadisha",
        "Initials": "N"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Research Complex at Harwell, Rutherford Appleton Laboratory, Oxon, OX11 0FA, UK."
          }
        ],
        "LastName": "Carr",
        "ForeName": "Stephen",
        "Initials": "S"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Quadrucept Limited, 1010 Cambourne Road, Cambridge, CB23 6DW, UK."
          }
        ],
        "LastName": "Ali",
        "ForeName": "Hanif",
        "Initials": "H"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Institute of Cancer Research, 15 Cotswold Road, Sutton, London, SM2 5NG, UK."
          }
        ],
        "LastName": "Van Montfort",
        "ForeName": "Rob",
        "Initials": "R"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Institute of Cancer Research, 15 Cotswold Road, Sutton, London, SM2 5NG, UK. terry.rabbitts@icr.ac.uk."
          }
        ],
        "LastName": "Rabbitts",
        "ForeName": "Terence",
        "Initials": "T"
      }
    ],
    "GrantList": [
      {
        "Acronym": "WT_",
        "Agency": "Wellcome Trust",
        "Country": "United Kingdom"
      },
      {
        "GrantID": "20289/Z16/Z",
        "Acronym": "WT_",
        "Agency": "Wellcome Trust",
        "Country": "United Kingdom"
      },
      {
        "GrantID": "2018-05766",
        "Agency": "Swedish Research Council",
        "Country": ""
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, Non-U.S. Gov't"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Sci Rep",
    "NlmUniqueID": "101563288",
    "ISSNLinking": "2045-2322"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antiviral Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Spike Glycoprotein, Coronavirus"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "spike protein, SARS-CoV-2"
    },
    {
      "RegistryNumber": "EC 3.4.17.23",
      "NameOfSubstance": "ACE2 protein, human"
    },
    {
      "RegistryNumber": "EC 3.4.17.23",
      "NameOfSubstance": "Angiotensin-Converting Enzyme 2"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "chemistry",
        "metabolism",
        "pharmacology"
      ],
      "DescriptorName": "Angiotensin-Converting Enzyme 2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Animals"
    },
    {
      "QualifierName": [
        "chemistry",
        "metabolism"
      ],
      "DescriptorName": "Antiviral Agents"
    },
    {
      "QualifierName": [
        "enzymology",
        "prevention & control",
        "virology"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Cell Line"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Design"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Haplorhini"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Protein Binding"
    },
    {
      "QualifierName": [
        "methods"
      ],
      "DescriptorName": "Protein Engineering"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Protein Structural Elements"
    },
    {
      "QualifierName": [
        "drug effects",
        "isolation & purification",
        "metabolism"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [
        "antagonists & inhibitors",
        "metabolism"
      ],
      "DescriptorName": "Spike Glycoprotein, Coronavirus"
    },
    {
      "QualifierName": [],
      "DescriptorName": "COVID-19 Drug Treatment"
    }
  ],
  "CoiStatement": "Terence Rabbitts and Hanif Ali are stake holders in Quadrucept Ltd. None of the other authors have any conflicts of interest to declare."
}